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Abstract
Background:  Nuclear mitochondrial pseudogenes (numts) are a potential source of
contamination during mitochondrial DNA PCR amplification. This possibility warrants careful
experimental design and cautious interpretation of heteroplasmic results.
Results: Here we report the cloning and sequencing of numts loci, amplified from human tissue
and rho-zero (ρ0) cells (control) with primers known to amplify the mitochondrial genome. This
paper is the first to fully sequence 46 paralogous nuclear DNA fragments that represent the entire
mitochondrial genome. This is a surprisingly small number due primarily to the primer sets used in
this study, because prior to this, BLAST searches have suggested that nuclear DNA harbors
between 400 to 1,500 paralogous mitochondrial DNA fragments. Our results indicate that multiple
numts were amplified simultaneously with the mitochondrial genome and increased the load of
pseudogene signal in PCR reactions. Further, the entire mitochondrial genome was represented by
multiple copies of paralogous nuclear sequences.
Conclusion: These findings suggest that mitochondrial genome disease-associated biomarkers
must be rigorously authenticated to preclude any affiliation with paralogous nuclear pseudogenes.
Importantly, the common perception that mitochondrial template "swamps" numts loci precluding
detectable amplification, depends on the region of the mitochondrial genome targeted by the PCR
reaction and the number of pseudogene loci that may co-amplify. Cloning and relevant sequencing
data will facilitate the correct interpretation. This is the first complete, wet-lab characterization of
numts that represent the entire mitochondrial genome.
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Background
The unique maternal inheritance pattern of mitochon-
drial DNA (mtDNA), its small genome size, accelerated
mutation rate, lack of recombination, and multiple copy
number per cell, in comparison to nuclear DNA, are ideal
biological traits for investigating evolution, population
genetics and for forensic and medical applications. Thus,
the mitochondrial genome has been used as a biosensor
for the timing and movement of human populations in
antiquity [1,2]. MtDNA analysis is routinely used in foren-
sic biology to type biological material when degradation
prevents nuclear STR amplification [3]. In addition, the
entire mitochondrial molecule has potential medical util-
ity because it can serve as a repository of cancer mutations
and as a biosensor indicative of genetic alterations [4-13].
Frequently, identifying legitimate mtDNA mutations is
confounded by heteroplasmy, a condition in which wild-
type and mutant mitochondrial genomes co-exist in a cell.
The interpretation of heteroplasmy can further be con-
founded by the widespread integration of portions of the
mitochondrial genome into the nuclear genome [14,15].
These homologous, yet divergent nuclear and mtDNA
sequences can be co-amplified in PCR reactions intended
to replicate targeted mtDNA sequences only. Although
this problem has previously been considered to be muted
because of the high copy number of mtDNA over corre-
sponding nuclear loci, caution is warranted [16]. For
example, there are specific regions of the mitochondrial
genome that have corresponding nuclear mitochondrial
pseudogenes (numts) distributed across multiple chro-
mosomes. Hence, there are regions of the mitochondrial
genome that have a high nuclear copy number, which are
not completely "swamped" during amplification. We
report that some heteroplasmies detected in prostate can-
cer samples are a result of co-amplification of these multi-
ple loci.
A large number of manuscripts addressing errors related
to the interpretation of mtDNA and mtDNA hetero-
plasmy has been published [17-25]. Notably not all these
errors are due to pseudogene co-amplification; however,
mistakes from pseudogenes may increase with improved
sequencing methods and highly sensitive re-sequencing
microarray technologies that have a lower detection limit
than traditional sequencing and which readily detect low-
level heteroplasmy [11,26]. In some cases, if the hetero-
plasmy is inherited, it substantially increases the power of
mutation detection, which becomes an important aspect
since heteroplasmy has been reported as an early indica-
tion of disease [27-31]. In addition, if the disease process
invokes mitochondrial depletion, this could increase
nuclear pseudogene signal in reactions as a result of
reduced mitochondrial genome copy number [32]. Loss
of mitochondria has been described in several human
cancers [33-36]. As well, the number of mitochondria and
mtDNA copy number vary for different cell types [37-39].
These important matters relating to sequence interpreta-
tion have been generally neglected, in part, due to the lack
of numt reference material, which would help investiga-
tors determine the relevance of detected mtDNA sequence
variations. Hence, the need to validate somatic mitochon-
drial mutations is a pressing one.
Heteroplasmic issues have already complicated data
obtained from other species. For example, in elephant
hair, low mtDNA content is the reason why numts were
co-amplified and misinterpreted as authentic mtDNA. In
contrast, numts were not detected in DNA derived from
elephant blood due to the presence of mitochondria-rich
platelets [40]. Moreover, the hominid, Gorilla, is well
known for significant numt interference with mitochon-
drial sequences, highlighting the need for diligence when
interpreting human mtDNA heteroplasmy [41]. Not sur-
prisingly, the effort for using mitochondrial cytochrome c
oxidase as a primate "barcode" is plagued by numt ampli-
fication as well [42].
Further, laser capture microscopy has improved the ability
to separate and analyze cancer cells, but because of the
decreased amounts of sample DNA, many primer pairs are
required to obtain a robust amplification of the entire
mitochondrial genome [43]. Moreover, a sufficient
number of cells must be captured to avoid incorporation
errors associated with low template quantity [44]. This
will also be relevant to studies that use formalin-fixed par-
affin embedded samples [45]. The use of many primers
means that smaller amplicons will be synthesized trans-
lating into a higher risk of co-amplification of numts and
the potential misinterpretation of heteroplasmic calls.
There is limited in silico and wet-lab evidence indicating
that fragments of the human mitochondrial genome are
embedded in the nuclear DNA archive [46-50]. These
findings emphasize the critical need to minimize errone-
ous interpretation of heteroplasmy, a vital necessity for
precise forensic discrimination, evolutionary studies, and
potential diagnostics. We provide evidence of numts for
the entire mitochondrial genome by the amplification,
cloning, and identification of numts from rho-zero (ρ0)
cells and clinical cancer specimens. Here we present
results from overlapping primers, which co-amplified
nuclear embedded, paralogous mitochondrial sequence.
Surprisingly, our data shows a relatively small number
(when compared to hypothetical sequence information
obtained from BLAST searches) of multiple nuclear loci
that co-amplify with the mitochondrial genome. These
findings demonstrate that accurate interpretation of heter-
oplasmy not only requires careful primer design and test-
ing, but also indicates that a compendium of the sequenceBMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
Page 3 of 13
(page number not for citation purposes)
information from multiple-copy number numts is an
important reference tool that will facilitate correct mtDNA
interpretation and support reliable mitochondrial
genome sequencing data.
Results
ρ0 cells lack mtDNA
Rho-zero cells were evaluated for the presence of mtDNA.
To ensure that total DNA extracted from ρ0 cells were
indeed devoid of mtDNA, we first performed Southern
blot analyses on DNA extracts from ρ0 cells. Blood was
used as a positive control. No full length mitochondrial
genome signal was observed in ρ0 lanes when the blots
were probed with mtDNA-specific probes (Figure 1a). We
next performed PCR on the DNA extracts with primers
specific to the mitochondrial coding regions. Again, there
were no amplifications observed in the ρ0  templates,
while DNA isolated from blood was amplified, as
expected (data not shown). We used RT-PCR to provide
further evidence that ρ0 cells are indeed devoid of mtDNA
[51]. RT-PCR analysis was performed on RNA samples
from ρ0 cells and normal human skin tissue (epithelial
cells) samples with primers to OXPHOS genes and a
nuclear gene (positive control), 5-aminolevulinate syn-
thase (hALAS) (Table 1). Whereas the hALAS primers
amplified nuclear targets in template from ρ0 and epithe-
lial cells, there was no observable product with mtDNA
primers for the ρ0 cDNA template (Figure 1b), independ-
ently confirming the absence of mtDNA in these cells.
Co-amplification of numts and mtDNA
Amplification of the complete mitochondrial genome was
performed on human formalin fixed and paraffin embed-
ded (FFPE) prostate cancer samples using a set of 34 prim-
ers (Table 2). Due to the amount and quality of DNA
recovered, the average amplicon size was limited to 625
bp. Surprisingly, 24 (71%) of the primer sets co-amplified
mitochondrial pseudogenes (Figure 2, and data not
shown). A similar ratio was previously reported by an
independent group using 38 primers (26/38 or 68%)
[16]. In an effort to fully characterize numts that represent
the entire mitochondrial genome, we redesigned the
remaining 10 primers to co-amplify nuclear loci. Thus, we
amplified template from ρ0 cells and subsequently identi-
fied (via sequencing) the cloned fragments from the
nucleus. A region of the D-loop (base pairs 16211-420
and 15-711) was recalcitrant to co-amplification using
our mitochondrial primers. Therefore, two chromosome
17 specific primers were designed to capture this D-loop
fragment (Table 2). Hence, a total of 36 primer sets were
used to recover the entire mitochondrial genome from the
nucleus. The sequences representative of the entire mito-
chondrial genome are provided as an additional material
(additional file 1). Figure 3 is an example of an alignment
to rCRS of three numt clones recovered using primer set
1488F/2084R (Table 2). These three clones were recov-
ered form three separate chromosomes (Chr11 –
NT_009237, Chr5 – NT_006713, and Chr3 –
NT_005612). Similar alignment of our consensus cloned
sequences enabled the assembly of a pseudo-mitochon-
drial genome (Figure 4).
The following chromosomes were represented in the data:
1, 2, 3, 4, 5, 7, 8, 9, 11, 16, 17, 20 and X. The number of
paralogous sequences, in some instances, was lower than
the number predicted from BLAST searches (Figure 3, 5).
We demonstrate that there are only a limited number of
multiple copy numts that potentially contribute to a het-
eroplasmic signal. Subsequently, we systematically
inspected heteroplasmic sites observed in sequences from
the prostate cancer samples for numt contribution using
our cloned ρ0 data as a reference. We discovered false het-
ρ0 cellscells do not contain mtDNA Figure 1
ρ0 cells do not contain mtDNA. a. Southern blot analysis 
of total DNA extracted from blood (bld) and ρ0 cells and 
probed with a full length mtDNA probe.  Note the absence 
of hybridization to ρ0 extracts. Lad is a DIG-labeled DNA 
molecular weight marker III (Roche).  b. PCR amplification of 
cDNA from ρ0 and epithelial cells (EC). Note the amplifica-
tion of ρ0 cDNA with primers to the nuclear gene hALAS, 
whereas primers to ND1, ATPase6, and CYTB failed to 
amplify ρ0 cDNA, although they all amplified cDNA from EC.  
Lad is a 100bp DNA size standard (Fermentas life sciences). 
Lad         bld ρo Lad       ρ0        ρ0 EC      ρ0 EC      ρ0 EC
a                              b
hALAS ND1          ATPase6        CYTB
21226
5148
4973
4268
Table 1: Sequences of four primer sets used in RT-PCR.
Designation Primer sequence (5'-3')
hALASF CCACTGGAAGAGCTGTGTGA
hALASR ACCCTCCAACACAACCAAAG
ND1F GAGCAGTAGCCCAAACAATC
ND1R GGGTTCGGTTGGTCTCTGCTAG
ATP6F CCATAAAATTATGAGCGGGCACAGTGATT
ATP6R GGAAGGTTAATGGTTGATATTGCTAGG
CYTBF CTAGCAACACTCCACCTCCTAT
CYTBR GTAAGCCGAGGGCGTCTTTGCTTGBMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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eroplasmic sites occurred when there was co-amplifica-
tion of multiple numt loci with the same nucleotide at
that particular site. Base pairs 1709, 1711 and 1719 in one
specific amplicon (1488–2084, 16S rRNA) illustrate this
point. The amplification of this specific region of the
mitochondrial genome also co-amplified numts on chro-
mosomes 3, 5 and 11 (Figures 3, 6). All three chromo-
somes have an A as opposed to a G, which correspond to
mitochondrial positions 1709 and 1719. Using auto-
mated DNA sequencing, these multi-copy numts were
detected as heteroplasmies at positions 1709 and 1719
(Figure 6). At position 1711, chromosomes 5 and 11 have
a C as does the tissue; however, chromosome 3 has a T. A
weak heteroplasmic signal is evident by a minute T peak,
but because of the poor detection limit of fluorescent
sequencing, this peak is virtually equivalent to back-
ground (Figure 6). Heteroplasmic signals were detected
for other sites as well. For instance, the primer pair for the
amplicon (3230–3893) co-amplified homologous numts
on 5 different chromosomes (2, 4, 16, 17 and X). This
region is evident in the pseudo-mitochondrial genome
assembly from our clones (Figure 4).
Multiple numt copies exist in the genome
To cross-validate our cloned data, we analyzed genomic
DNA from ρ0 cells, blood, and human placenta using
mitochondrial primers that co-amplified nuclear loci in
the prostate cancer specimens. In blood and human pla-
centa samples, a single mtDNA amplicon was consistently
observed (Figure 7, and data not shown). Although
sequence analysis of the prostate specimens detected
numts, their signals were below the detection limit of aga-
rose gel electrophoresis. In contrast, several primers con-
sistently amplified numts from ρ0 cells generating high
molecular weight amplifications in addition to the
expected mtDNA fragments (Figure 7). These findings
confirm the presence of multiple numts loci in the
genome and translate into real concern that numts are
present in amplifications that produce more that one
band or different size amplicons.
Survey of mitochondrial genome mutations associated 
with disease suggests caution
Based on our findings that false heteroplasmic sites
occurred when there was co-amplification of multiple
numt loci with the same nucleotide at that particular site,
we compared our cloning data to possible disease associ-
ated mutations listed on MITOMAP [52] and common
sites were noted. In addition, a BLAST search was per-
formed for these sites and hits held in common between
the marker and cloning information were scored as well.
Numerous commonalities were noted, which is cause for
concern (Table 3).
Discussion
In this study, we recovered and assembled the entire mito-
chondrial genome from nuclear loci. Moreover, this
"pseudo-mitochondrial genome" involves numts from
over half of the human complement of chromosomes,
including the X chromosome. This suggests a widespread
allocation of numts in the human nuclear genome. Sur-
prisingly, this distribution was achieved with primers rou-
tinely used to amplify mtDNA, yet designed without
consideration for numts. Seventy-one percent (24/34) of
the primers co-amplified numts in prostate cancer tissue
samples. This validates prior suggestions that numts are a
potential source of misinformation and serves to illustrate
the ease of co-amplification of both mtDNA and nuclear
embedded paralogous mitochondrial DNA sequences
[16]. Our data demonstrate that contrary to a consensus
of opinions that the copy number of the mitochondrial
genome "swamps" the signal from numts loci, there are
circumstances which favor PCR recovery of numts, such as
multiple pseudogene copy number [18]. For instance, het-
eroplasmic mutations had been associated with late-onset
Alzheimer's disease [17,53]; however, these false hetero-
plasmies resulted from co-amplification of numts
[19,54,55]. Indeed, human numts perplexed ancient DNA
studies as well when it was reported that DNA had been
recovered and amplified from a Cretaceous dinosaur bone
[56]. This sequence corresponded to a human numt con-
taining cytochrome b sequence [57], probably from rea-
gent or sample contamination.
Direct pseudogene contribution is not always obvious
and can confound suggested mtDNA biomarkers. For
example, one set of primers in our data set amplifies
tRNAleu and ND1 (3230–3893). Subsequent cloning data
Numts co-amplify from clinical samples Figure 2
Numts co-amplify from clinical samples. A representa-
tive gel picture showing amplification of clinical samples with 
primers that also amplify ρ0 template is shown. Unlabelled 
lanes are the clinical samples.  Subsequent analysis of 
sequences from this amplification (see Figure 5) revealed the 
presence of pseudogene contamination.BMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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Example of an alignment of three clones Figure 3
Example of an alignment of three clones. Example of an alignment of three clones (clones G C11. A1, G C3. A1 and G 
C5.C1) recovered from three chromosomes (Chr11 - NT_009237, Chr5 - NT_006713, and Chr3 - NT_005612) to the rCRS 
is shown.
aBMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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Table 2: 5' genome location (according to rCRS) and primer sequences for 36 primers including 34 (#3–36) used to amplify formalin 
fixed, paraffin embedded tissue. Primers in bold (1, 2) indicate chromosome (Chr) 17 specific primers redesigned to capture rest of D-
loop fragment. The region spanned by 15971–16410 was split into two separate amplicons for the ρ 0 amplification (15673–16009 and 
15777–16398).
Primer Sequence (5'-3') Mitochondria Position Chr Accession Number Nuclear Position
1 16319F ATC GCT CAT GGT AGA TAG CAC 16319-446 17 NT_024862.13 337395–338087
446R TGT TAG TTG AGG GGT GAC TGTT
2 374F AAT CCA ACT CAA CCA GAG CCC A 371–461 17 NT_024862.13 338011–338101
781R TGA GCT GCA CTA ATG CGT GC Nuclear Gap 17 NT_024862.13 338102–338279
574–783 17 NT_024862.13 338280–338489
3 615F ATG TTT AGA CGG GCT CAC ATC ACC 651–1247 11 NT_009237.17 9318994-9318400
1247R CAA GAG GTG GTG AGG TTG ATC G
4 1051F ACA ATA GCT AAG ACC CAA ACT GGG AT 1062–1639 11 NT_009237.17 9318585-9318008
1644R CTC CTA AGT GTA AGT TGG GTG CTT TG 1068–1618 5 NT_006713.14 30541827-30541277
5 1488F CGT CAC CCT CCT CAA GTA TAC TTC 1497–2049 11 NT_009237.17 9318150-9317598
2084R TAC AAG GGG ATT TAG AGG GTT CTG TG 1497–2049 5 NT_006713.14 30541398-30540846
1497–2049 3 NT_005612.14 2832399-2832340
6 1938F AGA GCA CAC CCG TCT ATG TAG CAA 1938–2612 11 NT_009237.17 9317709-9317035
2612R GGA ACA AGT GAT TAT GCT ACC TTT GCA C 1938–2612 3 NT_005612.14 2831958-2831284
1939–2612 17 NT_024862.13 339611-340281
1940–2612 8 NT_023678.15 902509-901844
1971–2612 5 NT_006713.14 30540924-30540284
7 2417F CAC TGT CAA CCC AAC ACA GGC AT 2402–3078 20 NT_011362.9 20987219-20986564
3101R TAG AAA CCG ACC TGG ATT ACT CCG 2417–3076 17 NT_024862.13 340090-340749
8 3021F CGC TAT TAA AGG TTC GTT TGT TC 3070–3673 17 NT_024862.13 340743-341346
3695R ATC AGG GCG TAG TTT GAG TTT G
9 3230F GTT AAG ATG GCA GAG CCC GGT AA 3253–3859 4 NT_016354.17 80880160-80879559
3893R GTT CGG TTG GTC TCT GCT AGT GT 3253–3870 2 NT_005058.14 9588111-9587524
3296–3870 16 NT_037887.4 3360917-3360343
3323–3870 X NT_011630.14 2761822-2761281
3347–3870 17 NT_024862.13 341020-341543
10 3728F CAT ATG AAG TCA CCC TAG CCA TC 3814–4391 17 NT_010718.15 19103293-19103865
4417R TTT AGC TGA CCT TAC TTT AGG ATG GG 3816–4391 17 NT_024862.13 341489-342064
11 4337F ATG AGA ATC GAA CCC ATC CCT GAG 4361–5010 1 NT_077913.2 43543-44192
5035R CAT CCT ATG TGG GTA ATT GAG GAG T
12 4867F GAC AAA AAC TAG CCC CCA TCT CAA 4866–5554 1 NT_077913.2 44048–44736
5646R GCT TAA TTA AAG TGG CTG ATT TGC GT 5169–5632 2 NT_005403.15 62851661-62852120
13 5468F CAC GCT ACT CCT ACC TAT CTC 5508–6124 17 NT_024862.13 343174–343794
6145R CAG TTG CCA AAG CCT CCG ATT ATG 5511–6121 1 NT_077913.2 44693–45303
14 5867F CAA TGC TTC ACT CAG CCA TTT TAC C 5892–6481 1 NT_077913.2 45074–45663
6482R GAC TGC TGT GAT TAG GAC GG
15 6418F AAC CCC CTG CCA TAA CCC AAT AC 6441–7056 1 NT_077913.2 45623-46239
7082R GAA GCC TCC TAT GAT GGC AAA TAC AG
16 6911F TGC AGT GCT CTG AGC CCT AGG ATT 6914–7521 1 NT_077913.2 46097-46704
7554R CTT TGA CAA AGT TAT GAA ATG GTT TTT CTA ATA 6935–7521 5 NT_034772.5 1804907-1804321
17 7400F CCC ACC CTA CCA CAC ATT CGA A 7453–8005 1 NT_077913.2 46636–47188
8029R GGC TTC AAT CGG GAG TAC TAC TCG
18 7829F CGC ATC CTT TAC ATA ACA GAC GAG G 7853–8472 1 NT_077913.2 47036–47622
8441R GTT GGG TGA TGA GGA ATA GTG TAA GG
17 8346F CAACACCTCTTTACAGTGAAATGCCC 8471–8941 1 NT_077913.2 47652–48122
8959R CGATAATAACTAGTATGGGGAT
20 8814F CCA ACT ATC TAT AAA CCT AGC C 8814–9427 1 NT_077913.2 47995–48594
9413R GCC TTG GTA TGT GCT TTC TCG TGT 8816–9375 5 NT_034772.5 1803025-1802466
21 9247F GCC CAT GAC CCC TAA CAG G 9268–9845 5 NT_034772.5 1802573-1801994
9868R CGG ATG AAG CAG ATA GTG AGG 9545–9859 7 NT_079592.1 56744603-56744909
22 9711F CTG GGT CTC TAT TTT ACC CTC C 9730–10300 5 NT_034772.5 1802112-1801539
10285R GGT AGG GGT AAA AGG AGG GCA
23 10198F CCC GCG TCC CTT TCT CCA T 10206–10768 5 NT_034772.5 1801633-1801071
10766R TTA GCA TTG GAG TAG GTT TAG G
24 10696F CCC TAC TAG TCT CAA TCT CCA A 10694–11509 9 NT_008470.17 2194293–2194999
11426R CTT CGA CAT GGG CTT TAG GGA G 10751–11426 5 NT_034772.5 36678748-36678073
25 11210F TTC TAC ACC CTA GTA GGC TCC CTT 11234–11786 5 NT_034772.5 36678265-36677713
11813R GTA GAG TTT GAA GTC CTT GAG AGA GGBMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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identified co-amplification of paralogous numts on five
chromosomes with this amplicon. Of specific interest are
bases 3316, 3496, 3697 and 3796, which are reported as
potential disease associated sites [52]. These sites are
problematic since the reported base changes are consist-
ent with pseudogene presentation in our data. Further,
results from new sequencing technologies have suggested
that homoplasmic signals may indeed be heteroplasmic
in nature [11]. In addition, the heteroplasmic patterns
seen at bps 3697 and 3796 are mirrored by the nuclear
pseudogene patterns (Table 3).
Re-examination of the raw data from the above studies
could address if the disease mutations are actually due to
co-amplified numts. Potential markers must be thor-
oughly investigated to preclude the inclusion of false
mutations in the interpretation of mtDNA mutations.
BLAST searches of nuclear pseudogenes belie the possibil-
ity of widespread integration and/or replication of these
sequences, since primers may amplify homologous numts
embedded elsewhere in the genome. Thus, high copy
numbers for these nuclear segments can produce poten-
tial misleading heteroplasmic signals.
Comparative marker studies require the same conditions
and primers for meaningful results. For example, pro-
posed MELAS sites T3250C and T3291C (tRNAleu) have
paralogous nuclear sites [58-60]. Follow-up work by Aka-
numa et al. (2000) [61], demonstrate a corollary numt
associated site for T3250C, but not T3291C. A BLAST
search shows that these competing sequences are on sep-
arate chromosomes (17 and 20) indicating comparison of
dissimilar data. In addition, the cloning data here identi-
fies similar regions on chromosomes 2, 4 and 17 (Table
3). Clearly there are numerous paralogous loci for mito-
chondrial tRNAleu, the amplification of which depends on
location and homology of primer sets.
Because of this association in our data, we compared our
cloning results to the suggested mitochondrial genome
disease associated sites listed on MITOMAP [52]. Results
suggest that many mutations require meticulous scrutiny
because of paralogous nuclear commonalities. Although
many of these mutations may well be actual disease mark-
ers, the possibility of numt association may confound
detection. For example, proposed prostate cancer muta-
tions (G5913A, G5973A and G6081A) are identified, by
cloning data, as resident on chromosomes 1 (2 homolo-
gous copies) and 17 even though the authors exercised
precautionary measures by scanning a database of known
nuclear pseudogenes [49,62]. A locus on chromosome 6
was identified as a potential co-amplification product, yet
chromosomes 1 and 17 were not detected. Co-amplifica-
tion of numts is primer dependent, which may explain the
differences seen here; however, database limitations and
the absence of extensive wet-lab numt data obscure the
meaning of the marker. Particularly suspicious are those
sites which demonstrate heteroplasmy in both normal
and disease tissue. This may reflect a consistent pattern of
numt amplification, an unintended characteristic of
primer design. A subset of the marker work prior to the
seminal numt work of Lopez et al. (1994) [14] may need
26 11629F AAT CAG CCA CAT AGC CCT CGT AG 11651–12205 5 NT_034772.5 36677848-36677294
12231R GTT AGC AGT TCT TGT GAG CTT TCT CG 11841–12206 5 NT_034772.5 1799998-1799633
27 12096F TCC TAT CCC TCA ACC CCG ACA T 12118–12681 5 NT_034772.5 36677381-36676818
12709R GGA AGA TGA GTA GAT ATT TGA AGA ACT G
28 12528F GAA CTG ACA CTG AGC CAC AAC C 12550–13070 5 NT_034772.5 1799289-1798769
13096R CAA CTA TAG TGC TTG AGT GGA GTA GG
29 12882F CAT CCT CGC CTT AGC ATG ATT TAT CC 12908–13493 5 NT_034772.5 36676591-36676006
13516R GGT CTT TGG AGT AGA AAC CTG TG 12908–13493 5 NT_034772.5 1798931-1798346
30 13239F CGT AGC CTT CTC CAC TTC AAG TC 13262–13827 5 NT_023148.12 2217633-2218198
13851R GTT GAG GTC TAG GGC TGT TAG AAG
31 13354F TTT ATG TGC TCC GGG TCC ATC AT 13377–13935 5 NT_023148.12 2217748-2218306
13957R CTA GAT AGG GGA TTG TGC GGT G
32 13838F CCC TAG ACC TCA ACT ACC TAA CC 13895–14454 5 NT_023148.12 2218266-2218823
14458R GAT GGC TAT TGA GGA GTA TCC T 14324–14535 5 NT_034772.5 36675175-36674964
33 14339F ACC CCA TCA TAC TCT TTC ACC C 14550–15042 5 NT_034772.5 1797288-1796796
15052R TAG GCC TCG CCC GAT GTG TA 14604–15051 5 NT_034772.5 36674895-36674448
34 14971F TGG CTG AAT CAT CCG CTA CCT T 15041–15785 17 NT_024862.13 336116-336858
15786R AAA GGG TAG CTT ACT GGT TGT CC 15345–15774 5 NT_023148.12 2219715-2220144
35 15673F ATC CAA ACA ACA AAG CAT AAT ATT TC 15672–15994 5 NT_023148.12 2220042-2220364
16009R AAT TAG AAT CTT AGC TTT GGG TG
36 15777F GCT ACC CCT TCA TCA CCT TC 15785–16388 17 NT_024862.13 336858-337463
16398R CAA CGG ACC ACT ATC TGA GGG
Table 2: 5' genome location (according to rCRS) and primer sequences for 36 primers including 34 (#3–36) used to amplify formalin 
fixed, paraffin embedded tissue. Primers in bold (1, 2) indicate chromosome (Chr) 17 specific primers redesigned to capture rest of D-
loop fragment. The region spanned by 15971–16410 was split into two separate amplicons for the ρ 0 amplification (15673–16009 and 
15777–16398). (Continued)BMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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clarification as well. For example, an ND2 lesion associ-
ated with Alzheimer's and Parkinson's diseases (G5460T/
A) has modulated T and A nucleotides. Both mutations
are seen in a BLAST search of numts. Moreover, our clon-
ing data also identifies a G at this point, but not a T, again
suggesting the relevance of primer selection; nevertheless,
all possible modulations are described in this early work
(see Kosel 1994. [63]), yet it remains a primary reference
for this lesion.
If the use of mitochondrial DNA and in particular somatic
mitochondrial genome mutations has important utility
The distribution of numt clones. Figure 4
The distribution of numt clones. The distribution of numt clones (based on our primers) across the rCRS reveals regions 
of the rCRS with multiple numts copies. The pseudo-mitochondrial genome assembled from consensus numt sequences.The 
distribution of numt clones across the rCRS reveals sites that could be problematic when primers are designed to targets in 
these regions. Clone name, chromosomal location and rCRS positions are indicated above each clone.
 
Mitochondria RCRS, 8,437 to 16,569
CLONE S CHR1, 8,437 to 8,941
CLONE T CHR1, 8,814 to 9,427
CLONE T CHR5, 8,816 to 9,375
CLONE U CHR5, 9,268 to 9,845
CLONE U CHR7, 9,546 to 9,859
CLONE V CHR5, 9,730 to 10,300
CLONE W CHR5, 10,206 to 10,768
CLONE X CHR9, 10,694 to 11,509
CLONE X CHR5-B, 10,751 to 11,426
CLONE Y CHR5-B, 11,234 to 11,786
CLONE Z CHR5-B, 11,651 to 12,206
CLONE Z CHR5, 11,841 to 12,206
CLONE AA CHR5-B, 12,118 to 12,681
CLONE BB CHR5, 12,550 to 13,070
CLONE CC CHR5, 12,908 to 13,493
CLONE CC CHR5-B, 12,908 to 13,493
CLONE DD CHR5-C, 13,262 to 13,827
CLONE EE CHR5-C, 13,377 to 13,935
CLONE FF CHR5-C, 13,895 to 14,454
CLONE FF CHR5-B, 14,324 to 14,454
CLONE GG CHR5, 14,450 to 15,042
CLONE GG CHR5-B , 14,604 to 15,051
CLONE HH CHR17, 15,050 to 15,760
CLONE HH CHR5-C, 15,345 to 15,774
CLONE II CHR5-C, 15,672 to 15,994
CLONE JJ CHR17, 15,785 to 16,388
CLONE A CHR17, 16,319 to 16,569
8,437 16,569
 
Mitochondria RCRS, 1 to 8,441
CLONE A CHR17 , 1 to 446
CLONE B CHR17 , 371 to 461
CLONE B CHR17, 568 to 780
CLONE C CHR11, 651 to 1,247
CLONE D CHR11, 1,062 to 1,639
CLONE D CHR5-D, 1,068 to 1,618
CLONE E CHR3, 1,497 to 2,049
CLONE E CHR11, 1,497 to 2,049
CLONE E CHR5-D, 1,497 to 2,049
CLONE F CHR3, 1,938 to 2,612
CLONE F CHR11, 1,938 to 2,612
CLONE F CHR17, 1,939 to 2,608
CLONE F CHR8, 1,940 to 2,612
CLONE F CHR5-D, 1,971 to 2,612
CLONE G CHR17, 2,417 to 3,076
CLONE G CHR20, 2,417 to 3,078
CLONE H CHR17, 3,070 to 3,673
CLONE I CHR4, 3,253 to 3,859
CLONE I CHR2, 3,253 to 3,870
CLONE I CHR16, 3,296 to 3,870
CLONE I CHRX, 3,323 to 3,870
CLONE I CHR17, 3,347 to 3,870
CLONE J CHR17, 3,816 to 4,391
CLONE J CHR17-B, 3,814 to 4,391
CLONE K CHR1, 4,361 to 5,010
CLONE L CHR1, 4,866 to 5,554
CLONE L CHR2, 5,169 to 5,632
CLONE L CHR1, 5,361 to 5,629
CLONE M CHR17, 5,508 to 6,124
CLONE M CHR1, 5,511 to 6,121
CLONE N CHR1, 5,892 to 6,481
CLONE O CHR1, 6,441 to 7,056
CLONE P CHR1, 6,914 to 7,521
CLONE P CHR5, 6,935 to 7,521
CLONE Q CHR1, 7,453 to 8,005
CLONE R CHR1, 7,853 to 8,442
1 8,442BMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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and medical merit, much of the data requires critical fol-
low-up from a pseudogene perspective. Amplification of
ρ0 DNA template with primers to identify and eliminate
those which co-amplify nuclear pseudogenes is a vital and
necessary procedure [16]. For example, mitochondrial
PCR protocols were simultaneously run on clinical sam-
ples and nucleic acid recovered from ρ0 cells to identify
and exclude co-amplification of numts in work by Coskun
et al. [64]. Alternatively, data may be screened by amplifi-
cation and sequencing of ρ0 derived DNA and conflicting
sites then backed out of actual data generated with identi-
cal primers; however, this approach is labor-intensive
[43]. Phylogenetic analysis of the data would also help
distinguish polymorphisms from authentic mutations
[22]. In general, and unfortunately the advice by Parfait et
al. has been largely ignored [16].
Our surprising results are not limited to short amplicons,
but are also detected in much larger amplicons. For exam-
ple, the overlapping amplification of chromosome 5 from
bp 8816 to 15051 cautions against assuming that long
amplicons are pseudogene free. These possibilities and
characteristics of the nuclear genome must be considered
when using mitochondrial sequence data for population,
forensic or disease studies. Although designing and testing
primers to avoid co-amplification of numts is a good lab-
oratory practice, compilation of numts representative of
the entire mitochondrial genome is valuable to catalog
and characterize the overall nuclear burden of these
sequences.
Conclusion
Amplification of overlapping numts paralogous to the
mitochondrial genome indicates that co-amplification of
nuclear mitochondrial pseudogenes is a real problem for
accurate sequence interpretation. Not only is co-amplifi-
A “piggyback” effect resulting from chromosomal  copy number and shared divergent sites is demon- strated in a patient sample. Figure 6
A “piggyback” effect resulting from chromosomal 
copy number and shared divergent sites is demon-
strated in a patient sample. The chromatogram is from a 
patient for whom heteroplasmy at positions 1709 and 1719 
were later noted tobe homologous to three chromosomes 
(3, 5, and 11), suggesting a possible co-amplification of numts 
in this instance.
Our primers recovered lower number of paralogous sequences compared to BLAST searches. Figure 5
Our primers recovered lower number of paralogous sequences compared to BLAST searches. A BLAST search 
using the rCRS region covered by the three clones (Figure 3a)returns more numts representative of this region(25)than the 
three  obtained by our cloning data.
 
Query                               ATA-TA-GC-AAGGACT-A-A-CCCC-T-ATACCTTCTGCATAATGAATTAACTAGAAAT   
NC_001807  1823           ATA-TA-GC-AAGGACT-A-A-CCCC-T-ATACCTTCTGCATAATGAATTAACTAGAAAT      1874 
NT_009237  9317826     ATA-CA-GC-AAGGACT-A-A-TCCC-T-GTACCTTCTGCATAATGAATTAACTAGAAAT      9317775 
NT_006713  30541074   ATA-TA-GC-AAGGACT-A-A-CCCC-T-GTACCTTCTGCATAATGAATTAACTAGAAAT      30541023 
NT_005612  2832075     ATA-CA-GC-AAGGACT-A-A-CCCC-T-GTACCTTTTGCATAATGAATTAACTAGAAAT      2832024 
NT_007914  2998897     AAA-TA-GC-AAGGA-T-AGA-CCCT-T-ATACCTTCTGCGTAATGAATTAACTAGAAAT     2998948 
NT_008413  33647858   A-A-TA-GC-AAAAA-T-AGA-CCCT-T-ATACCTTCTGCATAATGAATTAACTAGAAAT       33647908 
NT_008413  5082622     A-A-GA--C-AA-G--------CCCT-T-ATACCTTCTGCATAAAGTATTAAGTAGAAAT                 5082665 
NT_024862  339493       A-AGTA-GC-AAGGACA-A-A-CCCC-T-ATACCTTCTGCATAATGAATTAACTAGAAAT     339544 
NT_016354  80934604   A-A-AA-GC-AAAGAC--A-AGCCCT-T-ATACTTTCTGCATAATGTATTAACTAGAAAT       80934554 
NT_016354  41768304   A-A-AA-GC-AAAGAC--A-AGCTCT-T-ATACCTTCCGCATAATGTATTAACTAGAAGT       41768354 
NT_011630  2763299     A-A-AA-GC-AAAGACA-A-A-CCCT-T-ATATCTTCTGCATAATGTATTAACTAGAAAT       2763249 
NT_004836  2866222     A-A-AA-GC-AAAGA-TAA-A-GTCT-T-TTACCTTCTGCATAATGTACTAGCTAGAAAT       2866172 
NT_011362  20987791   A-A-AA-GC-AAAGAC--A-AGCCCT-T-ATACCTTCTGCATAATGCATTAACTAGAAAT      20987741 
NT_022135  6487931     A-A-AA-TC-AAAGAC--A-A-GCCC-T-ATACCTTTTGCATAATGTATTAACCAGAAAT        6487980 
NT_022135  29688448   AAA-AA-GC-AAAGA-T-A-A-ACCC-TTATACCTTCTGCATAATGTATTAACTAGAAAT     29688397 
NT_022135  32555841   AAA-AA-GC-AAAGACC-A-A-CCCT-T-ATACCTTCTGCATAATGTATTAACTAGAAAT     32555790 
NT_005403  62849509   AAA-AA-GC-AAAGAC--A-AGCCCT-T-ATACCTTCTGCATAATCTATTAACTAGAAAT     62849458 
NT_023678  902627       AAA--A-GC-AAAGACA-A-A-CCCT-T-ATACCTTCTGCATAATGTATTAACCAGAAAT      902577 
NT_022517  40234046   AAA--A-GC-AAAGAC--A-A-GCCC-TTATACCTTCTGCATAATGTATTAACTAGAAAT      40234096 
NT_007995  3190931     A-A-AA-GCAAAGCA-A-A-A-CCCT-T-ATACCTTCTGCATAATGTATTAACTAGAAAT      3190981 
NT_008583  5910010     A-A-AA-GC-AAAGACA-A-A-TCCT-T-GCATCTTTTGAATAATGAATTAACTAG-AAT       5910059 
NT_033899  6843028     AAA--A-GC-AAAGACA-A-A-CCCT-T-ATACCTTCTGCATAATGTATTAACTAGAAAT      6842978 
NT_010718  19100337   AAA--A-GC-AAAGACA-A-A-CCCT-T-ATACCTTCTGCATAA--------CTAGAAAT                 19100379 
NT_011786  26730286   A-A-AAGGC-AAAG-CT-A-ATCCCT-T-GTACCTTTTGCATAATGAATCAACTAG-CAT       26730336 
NT_008046  17314257   AAA-AA-AC-AAAG-CT-T-A-CCCCTT-ATGCCTTTTGCATAATGAATTAACTAG-AAC       17314307 BMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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cation dependent on the particular amplicon used, but
the copy number of these loci is also important. Only cer-
tain positions across the mitochondrial genome are asso-
ciated with multiple copies of numts. Mitochondrial DNA
heteroplasmy should be interpreted with caution since
they can be the result of nuclear/cytoplasmic co-amplifi-
cation. Herein, we have demonstrated the robust amplifi-
cation of numts. This paper is the first to fully sequence
the 46 paralogous DNA fragments that represent the
entire mitochondrial genome using 36 primer pairs. This
is a surprisingly low number, but reveals that only a lim-
ited number of paralogous numts are relevant when con-
sidering if heteroplasmic call are authentic mutations.
Compilation of a complete data set of numt sequences
will help others distinguish paralogous nuclear based het-
eroplasmy in forensic, population and medical applica-
tions.
Methods
Nucleic acid extraction
All research involving human tissue was approved by the
Thunder Bay Regional Health Sciences Centre Ethics
Committee in accordance with the Tri-Council Policy
Statement for Research Involving Humans http://
www.nserc.ca/programs/ethics.htm. Archived formalin
fixed and paraffin embedded (FFPE) prostatectomy sam-
ples were laser capture microdissected (LCM) and DNA
isolated by proteinase K digestion. DNA was isolated from
blood using the UltraClean™ DNA BloodSpin kit (MO
BIO laboratories, Inc). Human placenta DNA was pur-
chased from Sigma-Aldrich (D4642). ρ0cells were pre-
pared from a human osteocarcoma cell line 143B (ATCC
CRL-8303) treated with ethidium bromide to deplete
cytoplasmic mitochondrial DNA(kindly provided by Eric
Shoubridge) [65]. Cells were grown to confluence in high
glucose DMEM with pyruvate, L-glutamine, uridine (50
µg/ml) and 5% FBS. At confluence cultures were harvested
and DNA was extracted using QIAmp DNA Mini Kit.
Amplification, cloning and sequencing
Template from FFPE tissue samples and ρ0 cells were
amplified using 34 mitochondrial and 2 chromosome 17
primers. Using TaKaRa LA Taq DNA polymerase (Takara
Bio Inc.), PCR reactions were performed using the follow-
ing conditions: 1X LA PCR Buffer II (Mg2+plus), 0.4 mM
each dNTP mixture, 1X BSA (New England Biolabs Inc.),
0.6 µM each primer, 1.25 Units LA Taq, 0.5% Ficoll 400
and 1 mM tartrazine (20,195-2, Aldrich). Total reaction
volume was 25 µl. Cycling parameters were 94°C for 2
minutes, followed by 40 cycles of 94°C for 20 seconds, 30
seconds annealing at primer-specific optimized tempera-
tures, and 72°C for 90 seconds. Cycling was performed on
a DNA Engine Tetrad 2 (Bio-Rad, Hercules, CA). PCR
products were purified, cloned and sequenced at Lark™
Technologies using in-house standard operating proce-
dures (Houston, Texas). In general, 40 clones from each
ρ0 amplicon were selected and sequenced in both forward
and reverse directions.
Analysis
Sequences were analyzed using the Phred-Phrap-Consed
software package [66]. The sequences were then grouped
based on similarity and a megaBLAST search of NCBI
database was performed (using default parameters) to
identify all the nuclear co-ordinates of the fragments. This
enabled the chromosomal location and nuclear copy
number of each amplicon to be determined. Pairwise
sequence alignment was performed between the revised
Cambridge Reference Sequence (rCRS)[67] and the ρ0
clones from the suite of amplicons covering the entire
mitochondrial genome using the Sequencher™ soft-
ware(Gene Codes Corporation).
Southern Blotting
Mitochondrial genomes were cut with PvuII from 2 ug of
total DNA extracted from normal blood and ρ0 cells.
Digested product was electrophoresed through a 0.4%
agarose gel and blotted onto a membrane (Hybond-N+,
Roche Applied Sciences). Probes were generated from full
length mtDNA (16.5 kb) by random primer labeling
using the DIG System (Roche Diagnostics). Blots were
incubated with probe, washed, blocked, incubated with
anti-digoxigenin-AP fragments (Roche Applied Science)
Multiple numt copies are present in the nucleus Figure 7
Multiple numt copies are present in the nucleus. PCR 
amplification of total DNA extracted from ?0 and blood (bld) 
cells with primers targeting ND1, ATPase6 and CYTB genes. 
In contrast to the single amplicons obtained from blood, tem-
plate from ?0 contains additional high molecular weight ampli-
cons.  Lad is a 100bp DNA size standard (Fermentas life 
sciences).
Lad       ρ0 bld ρ0 bld ρ0 bld
ND1            ATPase6           CYTBBMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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and reacted with a chemiluminescent substrate (CDP-
Star®) and exposed to X-ray film (Kodak) as recom-
mended by the DIG Application Manual for Filter Hybrid-
ization (Roche Diagnostics, 2000).
PCR
For reverse transcriptase PCR analysis, total RNA was
extracted from ρ0 cells and a snap frozen skin sample
using standard protocols outlined in the RNeasy Micro Kit
manual (Qiagen). A DNase1 treatment step was included
in the RNA extraction process to ensure the complete
removal of all genomic DNA. We assessed RNA quantity
and quality with the ND-1000 spectrophotometer (Nano-
Drop®  technologies) and by gel electrophoresis. First
strand DNA was synthesized with the Omniscript® RT
(Qiagen) kit. 2 ul of the cDNA was amplified with primer
sets to coding mitochondrial genes and a nuclear gene, 5-
aminolaevulinate synthase (hALAS) (Table 3), using the
PCR conditions described above except the annealing
temperature for these primers was 54°C.
To examine for multiple copy numts, 50 ng of genomic
DNA from ρ0  cells, blood and human placenta were
amplified as described above, using primer sets to
OXPHOS genes,.
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Table 3: 
Locus Disease Allele Hom/Het BLAST hits Cloning data
Leu MM/CPEO T3250C -/+ C = 16; A = 1 C = 17
Leu CPEO C3254T +/- T = 18; A = 2 T = 2, 4 and 17
Leu MELAS T3291C -/+ C = 17 C = 2, 4 and 17
ND1 NIDDM; LHON; PEO G3316A +/- A = 17 A = 2, 4, 16, 17
ND1 LHON G3496T +/- T = 14; A = 2 T = X, 2, 4, 16, & 17
ND1 MELAS G3697A -/+ A = 3; C = 1 A = 2 & 4; G = X, 16, 17
ND1 Adult-Onset Dystonia A3796G -/+ G = 6 A = 2,4 & 17; G = X & 16
ADPD/Hearing Loss &
Gln Migrane T4336C +/+ C = 1 C = 17
ND2 AD;PD G5460T/A +/+ T = 5; A = 9 G = 1 (2); T = 2
Asn CPEO/MM G5703A -/+ A = 24 A = 17
COI PCA G5913A +/- A = 18; T = 1 G = 1(2); A = 17
Myogloinuria; Exercise
CO1 Intolerance G5920A -/+ A = 0 G = 1 (2); A = 17
CO1 PCA G5973A +/- A = 3 G = 1(2); A = 17
COI PCA G6081A +/- A = 1; T = 1 G = 1 (2); A = 17
Ser MM/Exercise Intolerance G7497A +/+ A = 14 A = 5
ATP6 LDYT G8950A +/- A = 2 A = 5
ATP6 Leigh Disease T9185C -/+ C = 1 C = 5
ND4 MELAS A11084G +/+ G = 9 G = 9
His MICM G12192A +/- A = 9 G = 5 (3); A = 2(5)
ND5 LHON G13708A +/- A = 15 A = 5 & 9
Paracrystalline Inclusions
CYTB with Exercise Intolerance G15497A +/- A = 2 A = 17
Thr Multiple Sclerosis G15927A +/- A = 5 G = 5; A = 17
Type 2 Diabetes;
D-Loop Cardiomyopathy T16189C +/+ C = 0 C = 17
Hom: homoplasmy; Het: heteroplasmy;BLAST hits: number of times a unique numt nucleotide location was returned with a BLAST search; 
Cloning data: designates chromosome(s) location of nucleotide from cloning data; AD: Alzeimer's Disease; ADPD: Alzeimer's and Parkinson's 
Disease; PD: Parkinson's Disease; CPEO: Chronic Progressive External Opthalmoplegia; PEO: Progressive External Opthalmoplegia; LDYT: 
Leber's hereditary optic neuropathy and Dystonia; MELAS: Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes; LHON: 
Leber's Hereditary Optic Neuropathy; MICM: Maternally Inherited Cardiomyopathy; MM: Mitochondrial Myopathy;NIDDM: Non-Insulin 
Dependent Diabetes; PCA: Prostate Cancer.BMC Genomics 2006, 7:185 http://www.biomedcentral.com/1471-2164/7/185
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